We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chronic Lymphocytic Leukemia Increases Peripheral Blood Hematopoietic Stem Cells

By LabMedica International staff writers
Posted on 31 Dec 2020
Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy invariably infiltrating the bone marrow. More...
The disease remains incurable, and after emergence of therapy, resistant disease patients succumb to infections because of secondary bone marrow failure.

The underlying mechanisms impairing normal hematopoiesis in patients with CLL are poorly defined. Mature, differentiated B cells, either pre- or post-germinal center, are considered the cell of origin of unmutated and mutated CLL, respectively. However, this paradigm has been challenged based on the observation of CLL-recurrent mutations present in a fraction of hematopoietic stem cells (HSCs).

Hematologists at the MRC Cambridge Stem Cell Institute (Cambridge, UK) and their colleagues assessed the frequency of hematopoietic stem and progenitor cells (HSPCs) in the peripheral blood (PB) of 69 individual patients with the diagnosis of CLL, and 21 age-matched healthy controls. PB samples were collected in the afternoon, when circulation of hematopoietic progenitors is known to reach its peak because of circadian oscillation.

To assess the absolute numbers of CD34+ cells, non-purified peripheral blood mononuclear cells from 5 mL PB were stained and gated for CD34 positivity and CD19 negativity to quantify the total amount of circulating hematopoietic progenitor cells, using precision counting beads (Biolegend, San Diego, CA, USA) and flow cytometry. Relative frequencies of HSPC subsets were assessed on CD34+-enriched cells using beads (Miltenyi Biotec, Bergisch Gladbach, Germany).

To assess differentiation capacity of HSPCs, 1 × 103 or 6 × 103 CD34+ cells were plated in duplicate in complete semisolid methylcellulose (STEMCELL Technologies, Vancouver, BC, Canada). Differentiated colonies were counted and scored based on morphology 14 days after culture in a humid environment at 37 °C using STEMCELL Technologies’ STEMVision camera and software.

The investigators reported that the absolute numbers of circulating HSPCs and found similar numbers of CD34+ cells to age-matched healthy individuals. The analyses revealed that common myeloid and myeloerythroid progenitors (CMPs-MEPs) (CD19CD34+CD38+CD45RACD10CD7) were more abundant in the PB of patients with CLL. Conversely, myelolymphoid progenitors (CD19CD34+CD38CD45RA+) were significantly decreased in patients’ blood compared with healthy controls. The HSC pool (CD19CD34+CD38CD45RA), defined as a pool of HSC and multipotent progenitors, is known to contain a heterogeneous pool of cells with different self-renewal and differentiation capacities, and was also more abundant in patients’ blood.

The authors concluded that their data provide further insights on the mechanisms causing cytopenia in patients with CLL and suggest that a pathologic mobilization of ST-HSCs is a contributing factor. The study was published on December 18, 2020 in the journal Blood Advances.

Related Links:
MRC Cambridge Stem Cell Institute
Biolegend
Miltenyi Biotec
STEMCELL Technologies



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.